Josh
Rose

In independent pharmacies across the country, something unusual is happening. A nurse walks in, sets up a tray, and runs a clinical trial visit - not in a hospital, not in a dedicated research site, but in the back of the kind of pharmacy where the pharmacist still knows your name. The company making this happen isn't on the front door. That's the point. And the person who designed the invisibility is Josh Rose.

Rose took the CEO seat at Hawthorne Health (then still called Hawthorne Effect) in early 2024. He arrived from CVS Health, where he had built the retail giant's clinical trial delivery division from the ground up. Before that, he spent more than a decade at IQVIA, eventually running their global decentralized clinical trial and mobile research nursing operation. Two decades of watching how the industry recruits patients. Two decades of watching who it misses.

The Problem Nobody Solved

Clinical research has a geography problem. Trials cluster around academic medical centers in major metros. Patients who don't live within driving range, who can't take time off work, who don't trust institutions they've never visited - they're out. The industry calls this a recruitment challenge. Rose calls it a design failure.

The conventional playbook threw technology at it: apps, telemedicine, digital consent forms. Decentralized Clinical Trials - DCTs - became the acronym of the decade. But Rose noticed something about the DCT wave: the technology worked, but the trust didn't travel. Patients in underserved communities weren't blocked by distance alone. They were blocked by unfamiliarity. They needed a face they already knew in a place they already went.

"I don't view us as DCT at all," Rose told Clinical Leader. "That's exactly what we have. It just happens to be in an independent pharmacy."

The Infrastructure Nobody Built

Hawthorne Health's model strips the operation down to what actually matters. The company provides the investigators, sub-investigators, clinical research coordinators, equipment, and operational infrastructure. The pharmacy provides the space, the patient relationships, and drug management. Patients walk into a place they've been going for years. They don't see "Hawthorne Health" anywhere.

"Hawthorne Health is behind the scenes," Rose explained. "Patients usually don't care who's running the clinical trial; they just want to feel like it's in a setting and with people they already trust."

The result is a network that reaches populations the traditional site model systematically excludes. Hawthorne targets what Rose calls "clinical research deserts" - communities outside major metros where access to trials has been effectively zero. The company selects pharmacy partners carefully: financially stable locations, at least two clinical rooms, and a geographic footprint in areas that haven't seen a research site before.

Watching What Failed at Scale

Rose's thinking about pharmacy-based research wasn't abstract. He watched what happened when large retail chains tried to enter the clinical trial space - the promise of scale colliding with the reality of institutional trust. Large retail pharmacies had the footprint but not the relationship. Independent pharmacies had the relationship but not the clinical infrastructure. Hawthorne's contribution is the infrastructure.

The company now operates across cardiovascular, dermatology, immunology, infectious disease, neurology, psychiatry, metabolic disease, COPD, asthma, dementia, and rare disease - a therapeutic breadth that reflects deliberate sponsor diversification rather than accidental growth.

Engineering the Invisible

There's a psychological precision to Hawthorne Health's branding strategy that the chemical engineer in Rose might appreciate. The company's name references the Hawthorne Effect - the psychological phenomenon where people change behavior when they know they're being observed. A clinical research company named after observer bias, built on the idea that the best research infrastructure is one patients can't see. The irony runs deep and apparently intentional.

The name "Hawthorne Heroes" for the field staff - the nurses and coordinators who show up in community pharmacies and patients' homes - adds another layer. In an industry where frontline clinical workers are chronically under-credited, Rose's company put them in the brand identity.

The RxE2 Partnership: Building the Network Others Couldn't

In January 2025, Hawthorne Health partnered with RxE2 - a pharmacist-led clinical trial services company - to create something neither could build alone. Hawthorne brings the GCP-trained mobile nurse network. RxE2 brings integrated pharmacists. Together, the partnership produces the largest combined community-based clinical trial network in the country, covering locations the traditional site model would never reach.

The partnership is a structural bet: that the future of patient recruitment isn't more aggressive digital advertising, but more trusted physical presence. That the bottleneck isn't awareness - it's access and belonging.

Building the Team for What's Next

In June 2025, Rose announced two senior hires: Ricky de Lemos as Chief Operating Officer (15+ years in clinical trial operations) and Marc Leighton as Chief Product Officer (17+ years in healthcare product leadership). Rose's characterization of the appointments was characteristically direct: "Ricky and Marc each bring a track record of measurable results and leadership in highly complex, fast-moving environments."

The framing is revealing. Not visionaries, not transformers - people with measurable results in complex environments. The vocabulary of someone who has watched the clinical trial industry overpromise on technology and underdeliver on operations for two decades.

Hawthorne Health now has a CFO, COO, CPO, CTO, CNO, CCO, Chief of Staff, and General Counsel. For a 150-person company, it's a leadership structure built for the next phase of scaling - not the current one. Rose is building the org chart for where the company is going, not where it is.

What He's After

The long-term ambition behind Hawthorne Health isn't another site network. Rose has described it in terms of elimination - eliminating clinical research deserts, eliminating the geographic and socioeconomic barriers that determine who gets access to experimental treatments. The company's stated reach of 50 million patients isn't a vanity metric - it's the map of who has been excluded and could, in theory, now be included.

For a chemical engineer who pivoted to healthcare strategy and spent two decades building the internal infrastructure of the industry's largest players, leading Hawthorne Health is the applied version of everything accumulated before. Not a departure. A destination.